报价延迟最少15分钟:2025/09/14 16:50 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.01/0.96
|
|
企业价值
5.42B
|
| 资产负债 |
|
每股账面净值
-0.36
|
| 现金流量 |
|
现金流量率
0.11
|
| 损益表 |
|
收益
2.79B
|
|
每股收益
7.36
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/14 16:50 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities. |
